ID   KTR3
AC   CVCL_E9WF
RX   PubMed=12842705;
RX   PubMed=15539083;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D200 ! KT-1 [Human leukemia]
SX   Male
AG   32Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=12842705; DOI=10.1016/s0301-472x(03)00089-4;
RA   Shimizu, Takatsune
RA   Miyakawa, Yoshitaka
RA   Oda, Atsushi
RA   Kizaki, Masahiro
RA   Ikeda, Yasuo
RT   "STI571-resistant KT-1 cells are sensitive to interferon-alpha
RT   accompanied by the loss of T-cell protein tyrosine phosphatase and
RT   prolonged phosphorylation of Stat1.";
RL   Exp. Hematol. 31:601-608(2003).
//
RX   PubMed=15539083; DOI=10.1016/j.exphem.2004.07.024;
RA   Shimizu, Takatsune
RA   Miyakawa, Yoshitaka
RA   Iwata, Satoshi
RA   Kuribara, Akiko
RA   Tiganis, Tony
RA   Morimoto, Chikao
RA   Ikeda, Yasuo
RA   Kizaki, Masahiro
RT   "A novel mechanism for imatinib mesylate (STI571) resistance in CML
RT   cell line KT-1: role of TC-PTP in modulating signals downstream from
RT   the BCR-ABL fusion protein.";
RL   Exp. Hematol. 32:1057-1063(2004).
//